Professor of Radiology, Radiation Oncology and Molecular Pathology, Director, Center for Molecular Imaging, Department of Radiology School of Medicine
Virginia Commonwealth University, USA
Dr. Zweit is a professor of Radiology, and affiliate professor of Radiation Oncology, Molecular Pathology, Biochemistry & Molecular Biology. He is the Director of the Center for Molecular Imaging and a senior member of the Massey Cancer Center at Virginia Commonwealth University Medical Center. He leads an inter-disciplinary and inter-collaborative molecular imaging research program that emphasizes multi-modality approaches to study biochemical and biological pathways in vivo. Professor Zweit’s research interests include the development of paradigms for molecular imaging, targeted therapeutics and nanotechnology strategies for preclinical and clinical translational research in cancer biology and therapeutics.
He is internationally recognized for his work in molecular imaging of cancer drug development, and conducted the “world’s first” Molecular PET Imaging clinical trial of Anti-angiogenic therapy in cancer patients (Journal National Cancer Institute 2002).
Professor Zweit serves as an advisor on a number of committees, including the Cancer Research UK Pharmacodynamic and Pharmacokiunetic Technologies Advisory Committee (Journal National Cancer Institute, 2006). He serves on the review body of a number of funding organizations, both in Europe and North America. He has supervised more than 25 MSc, MD and PhD theses. He has published more than 100 peer reviewed articles, over 250 conference abstracts, and 6 review articles and book chapters, as well as a few patents.
Professor Zweit obtained his PhD and DSc from the University of Manchester Medical School. Prior to that, he received his Nuclear Medicine training at the John F. Kennedy Medical Centre in New Jersey, and attended advanced Nuclear Medicine training at the Brooklyn Hospital in New York As an Undergraduate, he obtained his Bachelor of Science degree, in Radiation Biophysics, with a Biochemistry double major, from the University of Kansas.
His current research interests include radiopharmaceutical developments, Multi-modal probes, nanotechnology platforms, Tumor microenvironment, hybrid molecular imaging, and theranostic anti-cancer agents.